WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL RESEARCH

Research Article

2025
Volume: 02
Issue: 07
Page: 01-09

EARLY DETECTION, ADVANCED CARE: THYROID CANCER STRATEGY

Aman Chaurasiya[1], Ganesh Mahale[2], Unnati Sahu[3]* and Vanita Saharan[4]

[1]Pharmacist at Kokilaben Hospital, Mumbai, India.
[2]Professor of P. V. Polytechnic, SNDT Womens University, Santacruz, Mumbai, India.
[3]Student of P. V. Polytechnic College, SNDT Womens University, Santacruz, Mumbai, India.
[4]Head of Pharmacy Deparment, P.V.Polytechnic College, SNDT Womens University.

Received: 07 June 2025 **Revised: 27 June 2025** **Accepted: 17 July 2025**

Corresponding Author: Unnati Sahu
Address: Student of P. V. Polytechnic College, SNDT Womens University, Santacruz, Mumbai, India.
Email ID: sahuunnati530@gmail.com.

ABSTRACT
Thyroid cancer is most common endocrine malignancy, with rising incidence globally. Early detection through advanced diagnostics, Personalized treatment strategies, including surgery, targeted therapy, and immunotherapy, offers promising results.

KEYWORDS: Thyroid Cancer, Early Detection, Targeted Therapy.

INTRODUCTION
Thyroid cancer arises from the follicular or parafollicular cells of the thyroid gland and represents the most common malignancy of the endocrine system (American Cancer Society, 2024). Traditionally, thyroid carcinoma was viewed as a relatively rare entity with favorable prognosis, particularly the papillary subtype (Mayo Clinic, 2023). However, epidemiological trends over recent decades have demonstrated a marked increase in its incidence, raising questions regarding improved detection techniques versus environmental and genetic contributors (National Cancer Institute, 2023).

Historically, management centered on surgical excision and radioactive iodine therapy (WebMD, 2023). While these remain mainstays, the advent of molecular diagnostics and targeted therapies has revolutionized the landscape (IMR Press, 2022).Increased understanding of oncogenic pathways, such as those involving RET, BRAF, and RAS mutations, has deepened insights into thyroid tumorigenesis (IMR Press, 2022). Concurrently, the development of high-resolution ultrasonography and fine-needle aspiration biopsy (FNAB) has facilitated earlier detection of suspicious nodules, albeit at the risk of overdiagnosis and overtreatment (Cancer.Net, 2024). The integration of molecular profiling now allows more precise risk stratification and therapeutic decisions (Startus Insights, 2024).

Given these developments, this article aims to synthesize existing knowledge regarding the etiology, pathophysiology, diagnosis, and treatment of thyroid cancer while critically evaluating the shortcomings of earlier investigations. The primary objective is to highlight the significance of early detection and advanced, personalized treatment in optimizing clinical outcomes.

MATERIALS AND METHODS

Study Design and Data Sources

This article is a comprehensive literature-based review. Peer-reviewed publications, clinical guidelines, and epidemiological databases (e.g., National Cancer Institute, 2023; American Cancer Society, 2024; Mayo Clinic, 2023; WebMD, 2023) were reviewed. Relevant articles published between 2015 and 2024 were prioritized to ensure contemporary relevance.

Search Strategy

Databases searched include PubMed, Scopus, and Google Scholar using keywords: "thyroid cancer," "papillary thyroid carcinoma," "RET mutations," "radioactive iodine therapy," "FNAB," "thyroid nodule diagnosis," "immunotherapy in thyroid cancer," and "precision oncology thyroid."

Ethical Considerations

As this was a secondary data review using publicly accessible literature and did not involve human or animal experimentation, ethical approval was not required.

RESULTS

Epidemiological Trends

The incidence of thyroid cancer has risen substantially over the past two decades (National Cancer Institute, 2023). The American Cancer Society (2024) estimated 44,020 new cases in 2024 (12,500 in men and 31,520 in women). Fortunately, mortality remains low (~0.5 per

100,000 annually), reflecting the generally indolent nature of most subtypes (American Cancer Society, 2024).

Etiological Factors

Genetic: RET mutations, especially in medullary thyroid carcinoma, along with BRAF and RAS mutations in papillary and follicular types, are known drivers of carcinogenesis (IMR Press, 2022).

Environmental: Radiation exposure during childhood is a well-established risk factor. Additional risks include iodine deficiency or excess, dietary patterns, and obesity (Cleveland Clinic, 2023).

Syndromic Associations: Genetic conditions such as Multiple Endocrine Neoplasia (MEN) types 2A and 2B are strongly associated with medullary thyroid carcinoma (Mayo Clinic, 2023).

MOLECULAR MECHANISM

Key molecular mechanisms include dysregulation of MAPK and PI3K/AKT pathways, both of which promote tumorigenesis (IMR Press, 2022). The BRAF V600E mutation is particularly common in papillary thyroid carcinoma, found in over 60% of cases, and leads to aggressive clinical behavior (PMC, 2023). RET/PTC rearrangements and RAS mutations similarly contribute to cellular proliferation and metastasis (IMR Press, 2022).

Mutations: These are permanent changes in the DNA sequence of genes that can lead to the creation of abnormal proteins or the loss of protein function. Common mutations found in thyroid cancer include:

BRAF mutations: These mutations are found in papillary thyroid carcinoma (PTC), the most common type of thyroid cancer. They increase the activity of the MAPK pathway, promoting uncontrolled cell growth and division.

RAS mutations: These mutations can also occur in PTC and follicular thyroid carcinoma (FTC), another common type. They similarly activate the MAPK pathway.

RET mutations: These mutations are specific to medullary thyroid carcinoma (MTC) and lead to the overactivation of the RET signaling pathway, crucial for MTC development.

Gene rearrangements: These occur when pieces of different genes are abnormally joined together, creating a fusion gene that encodes a dysfunctional protein. Examples include.

RET/PTC rearrangements: These are found in PTC and lead to the constitutive activation of the RET signaling pathway.

Copy number alterations: These involve gains or losses of entire gene copies, leading to abnormal protein expression.

DIAGNOSIS

Thyroid cancer is a complex disease that requires thorough and accurate diagnostic methods to ensure proper treatment planning. The process typically involves several steps, starting with identifying potential symptoms and signs followed by various imaging techniques and laboratory tests. Here's an overview of the key aspects in diagnosing thyroid cancer.

Early-stage thyroid cancer is often silent, but as it grows, it may cause one or more of the following symptoms:

A nodule or lump in the front of the neck

Swelling or pain in the neck or throat

Difficulty swallowing or breathing

Hoarseness or changes in voice

Persistent cough or sore throat

Enlarged lymph nodes in the neck

Diagnostic Modalities

Ultrasound: An ultrasound uses sound waves to create an image of your thyroid gland. This can help identify any lumps or nodules and also determine the size, shape, and location of thyroid nodules, and whether they are solid or fluid-filled. It can also show if the cancer has spread to the nearby lymph nodes.(Mayo Clinic, 2023).

Fine Needle Aspiration Biopsy (FNAB): A fine needle aspiration biopsy is considered the gold standard for confirming the presence of malignancy in thyroid lesions. This procedure involves inserting a thin needle through the skin and into the thyroid nodule.

The needle removes a small sample of cells, which are then examined under a microscope to look for signs of cancer. This is the most accurate way to diagnose thyroid cancer. (Cancer.Net, 2024).

Blood Tests: Several blood tests can be ordered to assess thyroid function and identify potential markers for cancer. These tests measure the levels of thyroid hormones (T3, T4) and thyroid-stimulating hormone (TSH) produced by the gland. Additionally, specific blood tests may check for the presence of certain proteins associated with certain types of thyroid cancer. (WebMD, 2023).

Radioiodine Scan: This test uses a radioactive form of iodine (I-131) that is swallowed or injected into the body. The iodine is taken up by the thyroid cells, and a special camera detects the radiation. This test can show how active the thyroid cells are, and whether the cancer has spread to other parts of the body. This test is mainly used for differentiated thyroid cancers (papillary, follicular, or Hürthle cell), which absorb iodine. It is not used for medullary thyroid cancer, which does not absorb iodine. (Mayo Clinic, 2023).

CT/PET/MRI: In some cases, other imaging tests, such as CT scan, or PET scan, may be used to help diagnose thyroid cancer or determine if it has spread to other parts of the body.

It's important to note that not everyone with a thyroid nodule will have cancer. In fact, most thyroid nodules are benign (not cancerous). However, if you have any symptoms or concerns about your thyroid health, it is important to see a doctor to get a proper diagnosis. (Cancer.Net, 2024).

Current Treatment Modalities

Surgery: Total or hemithyroidectomy based on tumor characteristics (WebMD, 2023).

Radioactive Iodine Therapy (RAI): Effective in differentiated thyroid cancers (Mayo Clinic, 2023).

Tyrosine Kinase Inhibitors (**TKIs**): Agents like lenvatinib and sorafenib have shown promise in RAI-refractory thyroid cancer (PMC, 2023).

Immunotherapy: Immunotherapy is a type of cancer therapy that harnesses the power of the immune system to fight cancer. Immunotherapy can either stimulate the immune system to attack cancer cells more effectively, or provide the immune system with artificial components, such as antibodies or cells, that can recognize and destroy cancer cells. (National Institute of Health, India)Some examples of immunotherapy are.

Monoclonal antibodies (MABs): These are laboratory-made proteins that can bind to specific antigens on cancer cells and trigger an immune response. MABs can also deliver drugs, toxins, or radioactive substances to cancer cells, or block the signals that help cancer cells grow and survive.

CAR T-cell therapy: CAR T-cell therapy is another form of immunotherapy that involves genetically engineering a patient's T cells to recognize and attack cancer cells.

Checkpoint inhibitors: These are drugs that block the molecules that cancer cells use to evade the immune system, such as PD-1, PD-L1, and CTLA-4. By releasing the brakes on the immune system, checkpoint inhibitors can enhance the ability of T cells, a type of immune cell, to kill cancer cells.

Cancer vaccines: These are substances that can stimulate the immune system to produce antibodies or T cells that can prevent or treat cancer. Cancer vaccines can be made from cancer cells, parts of cancer cells, or antigens that are specific to cancer cells. Cancer vaccines can also be combined with other substances, such as adjuvants, that can boost the immune response.

Precision Oncology

This is a type of treatment that uses genomic, molecular, and clinical data to tailor the best treatment for each individual patient. It can involve sequencing the DNA or RNA of the tumor or the patient, analyzing the expression or activity of genes or proteins, or testing the response or sensitivity of the tumor to different drugs. Some of the benefits of precision oncology are that it can improve the accuracy, efficacy, and safety of treatment, that it can reduce the trial and error, and that it can empower the patient and the doctor. Some of the challenges of precision oncology are that it can be costly, that it can be complex and heterogeneous, and that it can be limited by data and technology. Some examples of precision oncology are molecular profiling, liquid biopsy, and pharmacogenomics.

Nanoparticles

Nanoparticles are microscopic carriers that can be programmed to deliver drugs directly to cancer cells. It can involve designing and engineering nanoparticles, nanocarriers, nanosensors, or nanomachines to deliver, detect, or manipulate cancer cells or molecules. Some of the benefits of nanotechnology are that it can enhance the delivery, specificity, and functionality of drugs or other agents, that it can overcome biological barriers and limitations, and that it can enable new modes of action and interaction. Some of the challenges of nanotechnology are that it can be toxic, that it can be cleared or eliminated by the body, and that it can be difficult to manufacture and characterize. Some examples of nanotechnology are gold nanoparticles, liposomes, and nanorobots.

Gene Therapy

This approach involves introducing genetic material into cancer cells to either kill them or make them more susceptible to other treatments.

It can involve inserting, deleting, or correcting genes in cancer cells or normal cells to alter their function or behavior. Some of the benefits of gene therapy are that it can be precise, that it can correct the underlying cause of cancer, and that it can be combined with other treatments. Some of the challenges of gene therapy are that it can be unpredictable, that it can have unintended consequences, and that it can be hard to deliver and regulate. Some examples of gene therapy are oncolytic viruses, gene editing, and gene silencing (Startus Insights, 2024)

Combination Therapies: Combining different types of cancer treatments, such as chemotherapy with immunotherapy, can often be more effective than using a single therapy alone. This allows for targeting different aspects of cancer cells and improving treatment outcomes. (Startus Insights, 2024).

DISCUSSION

The rising incidence of thyroid cancer is largely due to improved detection from imaging modalities, which—while beneficial—can lead to overdiagnosis and overtreatment of indolent tumors (National Cancer Institute, 2023). Current evidence suggests not all small papillary carcinomas necessitate immediate intervention, validating the use of active surveillance in select cases (Cancer.Net, 2024).

Molecular markers such as BRAF, RET, and RAS have refined risk stratification. For instance, the BRAF V600E mutation is associated with more aggressive disease and often justifies total thyroidectomy and postoperative RAI (IMR Press, 2022; PMC, 2023). The use of TKIs like lenvatinib has transformed outcomes in patients with refractory disease (PMC, 2023).

Past studies often lacked diverse populations and long-term follow-up, limiting generalizability (American Cancer Society, 2024). Methodological inconsistencies, narrow focuses on specific treatment modalities, and missing staging data were common limitations (National Cancer Institute, 2023).

The future lies in precision oncology: molecular profiling, AI-based diagnostics, and liquid biopsy may revolutionize care by allowing tailored treatment while minimizing unnecessary interventions (Startus Insights, 2024). Equitable access to these technologies remains a pressing global challenge.

CONCLUSION

This study highlights the necessity of early detection and personalized management in thyroid cancer. The interplay of genetic mutations, environmental exposures, and evolving diagnostics informs both prognosis and therapeutic approach. While traditional methods like surgery and RAI remain vital, emerging modalities such as immunotherapy, nanomedicine, and gene editing offer promising horizons (Startus Insights, 2024; PMC, 2023).Continued investment in innovation, global collaboration, and refinement of clinical practice guidelines are imperative to reduce morbidity and mortality from this increasingly prevalent malignancy.

REFERENCES

1. American Cancer Society. (2024). Thyroid cancer: Key statistics. Retrieved from https://www.cancer.org
2. National Cancer Institute. (2023). SEER cancer statistics review, 1975–2020. Bethesda, MD: National Institutes of Health. Retrieved from https://seer.cancer.gov
3. Cleveland Clinic. (2023). Thyroid cancer: Symptoms, causes, diagnosis & treatment. Cleveland Clinic. Retrieved from https://my.clevelandclinic.org
4. Mayo Clinic Staff. (2023). Thyroid nodules: Diagnosis and treatment. Mayo Clinic. Retrieved from https://www.mayoclinic.org
5. WebMD Editorial Contributors. (2023). What is thyroid cancer? Symptoms, causes, and treatment. WebMD. Retrieved from https://www.webmd.com

6. Cancer.Net Editorial Board. (2024). Thyroid cancer: Diagnosis and staging. Cancer.Net. American Society of Clinical Oncology. Retrieved from https://www.cancer.net
7. Zhao, L., Liu, D., & Xing, M. (2022). MAPK and PI3K pathways in thyroid carcinogenesis: Molecular mechanisms and targeted therapies. IMR Press. Journal of Molecular and Cellular Endocrinology.
8. StartUs Insights. (2024). Top 10 global cancer treatment trends in 2024. StartUs Insights. Retrieved from https://www.startus-insights.com
9. Tuttle, R. M., Haugen, B. R., & Perrier, N. D. (2023). Advances in thyroid cancer therapy: Targeted agents and molecular diagnostics. PubMed Central (PMC). Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064104
10. National Institute of Health, India. (2023). Immunotherapy in cancer treatment. Ministry of Health and Family Welfare, Government of India.